Exl-111 (MAD)

Phase 1Small molecule

EExcellergy Inc.

Exl-111 (MAD) is one of 24 small molecule programs targeting Allergic Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic DiseaseRecruiting

Allergic DiseasePhase 1

Recruiting

Competition

Competitive Landscape

23 competitors in Allergic Disease

#DrugCompanyPhaseTrials

Taxol

Teva

Approved

—2

Alvesco

AAzurity Pharmaceuticals

Claritin

Allegra

Zyrtec

Foradil

Xyzal

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Sudafed

Clarinex

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Study completion

NCT07356713

Clinical

Trials by Indication[1]

Unspecified1 trial

A Study to Find a Suitable Dose of Exl-111 for Further Research

Recruiting·EExcellergy Inc.·Phase 1·NCT07356713·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Exl-111 (MAD). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Exl-111 (MAD) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Exl-111 (MAD). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Excellergy Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EExcellergy Inc.

Exl-111 (MAD)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News